Mazen Hadid, MD
Interventional Cardiology · Chicago, ILNPI 1477704252
Payments from drug & device makers
Across 160 payments — averaging $54.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- W. L. Gore & Associates, Inc.$1K
- Abiomed$732
- Medtronic$601
- Penumbra, Inc.$472
- Johnson & Johnson$288
- plus $2K from 26 others
What the payments were for
- Travel & lodging$3,80844%
- Food & beverage$4,83556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $3,072 |
| W. L. Gore & Associates, Inc. | 8 | $1,283 |
| Abiomed | 8 | $732 |
| Medtronic(2 entities) | 10 | $601 |
| Penumbra, Inc. | 1 | $472 |
| Johnson & Johnson | 17 | $288 |
| Amgen | 18 | $267 |
| Novartis | 15 | $259 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $241 |
| Amarin Pharma, Inc. | 5 | $212 |
| Boehringer Ingelheim | 5 | $163 |
| ZOLL Medical Corporation | 1 | $146 |
| Kestra Medical Technology Services, Inc. | 2 | $144 |
| Surmodics, Inc. | 3 | $130 |
| Stryker | 3 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $90 |
| Pfizer | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 4 | $51 |
| Terumo Medical Corporation | 1 | $46 |
| AstraZeneca | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Boston Scientific | 1 | $27 |
| Cordis US CORP. | 1 | $23 |
| Resmed Corp | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Cardinal Health 200 LLC | 1 | $20 |
| Infobionic, Inc | 1 | $19 |
| EKOS Corporation | 1 | $18 |
| Sanofi | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$2,054
- GORE CARDIOFORM Septal Occluder$1,159
- Impella$607
- Indigo$472
- Omnilink Elite vascular stent system$313
- Xience Sierra Coronary Stent System$280
- Resolute$250
- TRICLIP$165
- Euphora$150
- Vascepa$125
- XARELTO$125
- JARDIANCE$111
How this compares
$8,644 in reported general payments places this provider in the 45th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $82,385 |
| XareltoRivaroxaban | 18 | $26,987 |
| EntrestoSacubitril/Valsartan | 17 | $22,030 |
| BrilintaTicagrelor | 18 | $17,873 |
| Metoprolol Succinate | 145 | $1,926 |
| Atorvastatin Calcium | 154 | $1,194 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 23 | $1,045 |
| Carvedilol | 123 | $836 |
| Ezetimibe | 26 | $834 |
| Losartan Potassium | 89 | $708 |
| ClopidogrelClopidogrel Bisulfate | 72 | $699 |
| Amlodipine Besylate | 64 | $655 |
| Rosuvastatin Calcium | 44 | $590 |
| Chlorthalidone | 29 | $577 |
| Valsartan | 11 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60 | $82,38571 claims |
| Johnson & JohnsonXarelto | $288 | $26,98718 claims |
| NovartisEntresto | $259 | $22,03017 claims |
| AstraZenecaBrilinta | $42 | $17,87318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Chicago
- Charles DavidsonChicago$5.8M
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Hussam SuradiChicago$455K
- Fareed Moses ColladoChicago$278K
- Keith BenzulyChicago$271K
- David StewartChicago$241K
- Sandeep KhoslaChicago$228K
- Daniel SchimmelChicago$221K
- Ranya SweisChicago$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.